September 2026 Research Update

This month, one hospital-based study added clearer clues about which people with polymyositis or dermatomyositis can do worse during a sudden flare of interstitial lung disease (scarring/inflammation in the lungs). The pattern in the results was that markers of stronger inflammation and weaker immune balance showed up more often in those who did not survive the hospital stay. The strongest single signal was a lower CD4 T-cell count, a type of white blood cell involved in immune control. [1]

In 35 hospitalized patients with an acute worsening of interstitial lung disease linked to dermatomyositis or polymyositis, the in-hospital death rate was 42.9%. People who were anti-MDA5 antibody positive had a higher in-hospital death rate (66.7%), and in that subgroup a lower CD4 count still predicted worse outcomes. Pleural effusion (fluid around the lungs), a higher neutrophil percentage (another white blood cell pattern), and higher CRP (a blood marker of inflammation) were also reported as independent warning signs. [1]

For patients and caregivers, this mainly adds understanding about risk during a very serious situation: being hospitalized for a sudden lung worsening in polymyositis or dermatomyositis. It does not test a treatment, but it suggests that certain routine findings (especially CD4 count and inflammation-related measures) may help explain why some hospital courses are more dangerous than others, including in people with anti-MDA5 antibodies. What remains uncertain is how well these signals hold up in larger groups and in other hospitals, and whether acting on them changes outcomes, since this study only compared survivors and non-survivors in routine care. [1]

Two studies this month filled in a more practical picture of living with inflammatory muscle diseases, including polymyositis: many patients have other health conditions alongside myositis, and the tests and treatments people receive can vary a lot by setting. One dataset (Brazil) described who is being seen and what care patterns look like, while another (Italy) focused on thyroid problems and how they relate to symptoms and complications. Put together, they reinforce that myositis is often managed as a whole-body condition, not only a muscle disease. [2] [3]

In the Brazilian REMAS registry of 284 adults with idiopathic inflammatory myopathies, polymyositis made up 9.1% of enrolled patients. The registry report showed wide use of prednisone (87%) and frequent use of medicines such as methotrexate (53.5%) and azathioprine (47.5%), along with smaller groups receiving treatments like IVIG (18.3%). It also highlighted that not everyone receives the same kinds of testing in routine care (for example, some had muscle MRI, EMG, or biopsy while many did not), which matters because it can affect how clearly subtypes and complications are documented. [2]

In a single-center group of 191 adults with inflammatory myositis, about half (51.8%) had a thyroid disorder. Having a thyroid disorder was reported more often in people with esophagus involvement (swallowing-related problems) and in those with osteoporosis or fragility fractures, and it was also linked to more total medical conditions and worse bodily pain scores on a quality-of-life questionnaire. The study did not find a link between thyroid disorders and myositis subtype or autoantibody groups in that clinic population. [3]

For patients, these findings mostly matter as context for what problems may come up alongside myositis and what care can look like in real clinics, rather than pointing to a new treatment. The registry data helps show how commonly different tests and medicines are used in practice, which can shape what gets recognized and recorded over time. The thyroid study suggests that thyroid disorders may be common in inflammatory myositis and may travel together with swallowing involvement, fracture risk, and higher pain burden, but it cannot prove that one causes the other because it was an observational comparison within one center. [2] [3]